The immune systems of the vast majority of people who have been infected with the CCP virus will continue to carry antibodies against the virus for at least 12 months, according to a peer-reviewed study accepted by the European Journal of Immunology on Sept. 24.
Scientists at the Finnish Institute for Health and Welfare studied the presence of antibodies in 1,292 subjects eight months after infection. They found that 96 percent of the subjects still carried neutralizing antibodies and 66 percent still carried a type of antibody called nucleoprotein IgG.
The scientists then investigated antibody levels one year after infection by randomly selecting 367 subjects from the original cohort who hadn’t yet been vaccinated. Eighty-nine percent of the subjects still carried neutralizing antibodies, and 36 percent still carried the IgG antibody.
Antibody levels were higher in subjects who had experienced severe COVID-19 disease. Compared to those who had mild disease, these subjects had two to seven times as many antibodies for at least 13 months after infection.
Despite lasting protection against the original strain of the CCP virus, the study found that the neutralization efficiency against the Alpha, Beta, and Delta variants waned over time. The reduction in efficiency was “considerably declined” for the Beta variant and was “only slightly reduced” against the Alpha variant. For the Delta variant, which is the dominant strain in the United States, the study found that 80 percent of the subjects still had immune protection 12 months after infection.
Despite the robust and lasting protection after an infection, CCP virus vaccine mandates in the United States offer no exemptions based on acquired immunity. An Epoch Times review of vaccine mandates for U.S. colleges and universities didn’t find a single school offering exemptions to students who had acquired immunity. Recent mandates imposed on the state and federal level have likewise ignored acquired immunity.